Denosumab (Prolia / Xgeva)

Denosumab is the real, FDA-approved monoclonal antibody this site's own calcitonin page already names as the modern osteoporosis standard sitting ahead of it — the missing anchor of this site's bone-density cluster alongside teriparatide, abaloparatide and calcitonin. A twice-yearly injection that blocks the RANKL protein driving osteoclast activity, it rests on a large, real placebo-controlled trial (FREEDOM, over 7,800 women) and has been marketed under two different brand names and dosing schedules since 2010. In January 2024, the FDA added a boxed warning after real dialysis-registry data found a severe, sometimes fatal hypocalcemia risk in patients with advanced kidney disease — a genuine, dated safety story on a drug that otherwise remains a first-line option.

What it is, and the cluster it completes

Denosumab is a fully human monoclonal antibody against RANKL (receptor activator of nuclear factor kappa-B ligand), a protein osteoclasts — the cells that break down bone — need to form, activate and survive. By binding RANKL and preventing it from reaching its receptor, denosumab shuts down osteoclast activity at its source, a mechanistically different route to the same antiresorptive goal as this site's calcitonin page's direct osteoclast-receptor blockade, and the opposite strategy entirely from the bone-building PTH-receptor agonism this site's teriparatide and abaloparatide pages describe. Amgen developed it, and the FDA approved it (as Prolia) on 1 June 2010 for postmenopausal women with osteoporosis at high risk of fracture — the drug this site's own calcitonin page already names, by name, as one of the treatments current guidelines place ahead of it.

The FREEDOM trial

Denosumab's approval rested on FREEDOM (Cummings SR, San Martin J, McClung MR, et al., "Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis," N Engl J Med 2009;361(8):756-765, PMID 19671655, DOI: 10.1056/NEJMoa0809493), a randomized, double-blind, placebo-controlled trial of 7,808 postmenopausal women with a bone mineral density T-score below -2.5, treated with 60mg subcutaneous denosumab or placebo every 6 months for 3 years. Versus placebo, denosumab reduced new vertebral fractures by 68% (2.3% vs 7.2%), hip fractures by 40% (0.7% vs 1.2%), and nonvertebral fractures by 20% (6.5% vs 8.0%) — a real, large, statistically significant result across all three fracture types, not just the spine.

One molecule, two brands, two regimens

Denosumab reaches the market as two distinct branded products, at different doses and schedules, for different patient populations — worth being precise about rather than treating as interchangeable. Prolia is the 60mg dose given once every 6 months, approved for osteoporosis and, in later label expansions, for bone loss from androgen- or aromatase-inhibitor cancer therapy and glucocorticoid-induced osteoporosis. Xgeva is a 120mg dose given monthly, approved separately by the FDA on 18 November 2010 for preventing skeletal-related events in patients with bone metastases from solid tumors, with giant cell tumor of bone added in June 2013 and hypercalcemia of malignancy refractory to bisphosphonates added later still — a much higher, more frequent dose because oncology patients need considerably stronger, sustained RANKL suppression than an osteoporosis patient does.

Two real safety stories: the 2024 boxed warning, and rebound fractures

On 19 January 2024, the FDA added a boxed warning to Prolia's label for severe hypocalcemia in patients with advanced chronic kidney disease, particularly those on dialysis. The finding behind it was concrete: in a real-world comparison of 1,523 women on dialysis starting denosumab against 1,281 starting an oral bisphosphonate, severe hypocalcemia within 12 weeks occurred in 41.1% of the denosumab group versus 2.0% of the bisphosphonate group — a stark, registry-scale disparity, with reported outcomes including hospitalization and death in the most severe cases. As of this review, that boxed warning applies to Prolia specifically; the FDA has not added the identical warning to Xgeva's label, worth stating precisely rather than assuming the two labels are identical just because the active ingredient is.

Current status: the first biosimilars

Amgen continues to market both Prolia and Xgeva, more than 15 years after the original approval. Starting in March 2024, the FDA approved the first denosumab biosimilars — Sandoz's Wyost and Jubbonti (denosumab-bddz), which also carry FDA interchangeability status and launched commercially in the US on 2 June 2025 — with several additional biosimilar pairs from other manufacturers approved through 2025. As a specialty osteoporosis and oncology biologic administered by injection in a clinical setting, denosumab has no wellness, bodybuilding or grey-market presence of any kind.